FDA Approves Lamzede (velmanase alfa-tycv) for the Treatment of Alpha-Mannosidosis

First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients Ultra-rare progressive disease presents with wide range of symptoms BOSTON, Feb. 16, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food […]
Continue reading »